# A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

> **NCT02020226** · PHASE1 · UNKNOWN · sponsor: **Threshold Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** TH-302

## Key facts

- **NCT ID:** NCT02020226
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-11
- **Primary completion:** 2016-07
- **Final completion:** 2016-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02020226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02020226, "A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02020226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*